Companies: 10,795·Total market cap: $144.5T
Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

AKBANASDAQHealthcare● Active
$0.94
+$0.00(+0.03%)
Market Cap$250982184
P/E Ratio
52W High$4.079
52W Low$0.875
SEC Filings

Akebia Therapeutics, Inc. (AKBA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001517022 · AKBA · NASDAQ · as of Jun 8, 2026

Filing snapshot

868
Total Filings
SCHEDULE 13G
Latest Form
2026-05-12
Most Recent
2014
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001517022 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001517022-26-000020
Primary Document
akba-20251231.htm
Source: data.sec.gov · CIK 0001517022 · Accession 0001517022-26-000020

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-05-07Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-12
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
ARSARS
ARS
2026-04-29
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-28
View
DEF 14AProxy Statement
DEF 14A
2026-04-28
View
PRE 14APRE 14A
DEF 14A
2026-04-15
View
3Initial Statement of Beneficial Ownership
PRIMARY DOCUMENT
2026-04-03
View
8-KCurrent Report
8-K
2026-04-01
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
10-KAnnual Report
10-K
2026-02-26
View
8-KCurrent Report
8-K
2026-02-26
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-09
View
3Initial Statement of Beneficial Ownership
PRIMARY DOCUMENT
2026-02-03
View
8-KCurrent Report
8-K
2026-01-30
View
Showing 1–15 of 515 filingsForm 4 / 144 hidden· 868 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001517022  |  Exchange: NASDAQ · Healthcare

Akebia Therapeutics, Inc. (NASDAQ: AKBA) has submitted 868 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001517022, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Akebia Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Akebia Therapeutics, Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical AKBA 10-K annual reports are available from 2011 through 2026.

Investors researching Akebia Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

AKBA SEC Filings · 8 questions

Akebia Therapeutics, Inc. (AKBA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 868 filings and access original documents at no cost. Akebia Therapeutics, Inc.'s CIK is 0001517022.

AKBA SEC filingsAkebia Therapeutics, Inc. SEC documentsfind AKBA 10-K